In general, endogenous IL-23 is suggested to promote tumor growth, demonstrated with many tumor models using IL-23A- or IL-23 receptor-deficient mice, while exogenous IL-23 is suggested to suppress tumor growth, demonstrated with many IL-23-overexpressing tumor cell lines 33. This evidence concerns the gene IL37 and neoplasm.